Discover
ONCY
Oncolytics Biotech Inc.
0.90
2 x 0.65
2 x 1.18
bid
ask
-
0.05
5.18%
2 @ 04:00 AM
0.93 +0.03 (3.41%)
| Ytd | 3.53% | |
| 1y | 14.01% |
0.90
day range
0.96
0.71
52 week range
1.51
| Open | 0.93 | Prev Close | 0.95 | Low | 0.90 | High | 0.96 | Mkt Cap | 107.50M |
| Vol | 649.41K | Avg Vol | 1.31M | EPS | -0.32 | P/E | N/A | Forward P/E | -3.02 |
| Beta | 1.51 | Short Ratio | 3.51 | Inst. Own | 1.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.91 | 200-d Avg | 1.02 | 1yr Est | 4.85 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.08 | -0.09 | -0.01 | -12.50% |
| 2024-08-01 | 2024-06 | -0.08 | -0.07 | 0.01 | 12.50% |
| 2024-05-09 | 2024-03 | -0.09 | -0.07 | 0.02 | 22.22% |
| 2024-03-07 | 2023-12 | -0.11 | -0.04 | 0.07 | 63.64% |
| 2023-11-03 | 2023-09 | -0.07 | -0.1 | -0.03 | -42.86% |
| 2023-08-14 | 2023-06 | -0.09 | -0.09 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-04 | Raymond James | Upgrade | Outperform | |
| 2024-03-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-06-29 | International Assets Investment Management, LLC | 198.40K | 179.71K | 0.26% |
| 2024-09-29 | Seeds Investor LLC | 189.94K | 172.05K | 0.25% |
| 2024-09-29 | Goldman Sachs Group Inc | 85.00K | 76.99K | 0.11% |
| 2024-09-29 | Royal Bank of Canada | 74.55K | 67.52K | 0.10% |
| 2024-09-29 | Citadel Advisors Llc | 79.25K | 71.78K | 0.10% |
| 2024-09-29 | Commonwealth Equity Services, LLC | 61.11K | 55.36K | 0.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 41.94K | 37.99K | 0.05% |
Split
| Split | Date |
|---|---|
| 10 : 95 | 2018-05-25 |